Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 16 Diseases   2 Trials   2 Trials   50 News 
  • ||||||||||  budesonide/formoterol / Generic mfg.
    Trial completion, Trial completion date:  As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period (clinicaltrials.gov) -  Aug 3, 2022   
    P3,  N=31, Completed, 
    Initiation date: Dec 2000 --> Dec 2022 Recruiting --> Completed | Trial completion date: Dec 2022 --> May 2022
  • ||||||||||  Onbrez (indacaterol) / Novartis
    Journal:  Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers. (Pubmed Central) -  Feb 4, 2022   
    Because of its design, the TB filter apparatus makes it possible to estimate regional deposition with inhalers directly using variable inhalation profiles without any additional equipment or changes to the experimental configuration. This method may be useful to expedite development of both innovative and generic drug products as it provides regional respiratory tract deposition estimates using fewer resources than exisiting methods.
  • ||||||||||  budesonide/formoterol / Generic mfg.
    Enrollment change:  As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period (clinicaltrials.gov) -  Oct 19, 2021   
    P3,  N=40, Recruiting, 
    This method may be useful to expedite development of both innovative and generic drug products as it provides regional respiratory tract deposition estimates using fewer resources than exisiting methods. N=100 --> 40
  • ||||||||||  budesonide/formoterol / Generic mfg.
    Trial completion date, Trial primary completion date:  As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period (clinicaltrials.gov) -  Mar 16, 2021   
    P3,  N=100, Recruiting, 
    Recruiting --> Completed | N=300 --> 120 Trial primary completion date: Sep 2020 --> Dec 2021 | Trial completion date: Aug 2021 --> Dec 2022
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Trial completion date, Trial primary completion date:  Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia (clinicaltrials.gov) -  Jan 12, 2021   
    P4,  N=300, Recruiting, 
    Trial primary completion date: Sep 2020 --> Dec 2021 | Trial completion date: Aug 2021 --> Dec 2022 Trial completion date: Oct 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
  • ||||||||||  budesonide / Generic mfg., Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    [VIRTUAL] Predicting Pharmacokinetics from Three Marketed Dry Powder Inhalers (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_2669;    
    In the present work, we link real-world emulative in vitro measurements of inhaler performance with numerical models of lung deposition and pharmacokinetics for budesonide (BUD) delivered from three marketed dry powder inhalers (DPIs) to illustrate how such a process can inform device/formulation design...Conclusions Coupling emulative in vitro experimentation with the modeling of regional lung deposition, ASL, and drug disposition allows for predictions of systemic drug exposure. The present method may prove useful in drug development.
  • ||||||||||  Preclinical, Journal:  An Exploration of Factors Affecting In Vitro Deposition of Pharmaceutical Aerosols in the Alberta Idealized Throat. (Pubmed Central) -  Jun 26, 2020   
    Three pressurized metered-dose inhalers (pMDIs; QVAR, Ventolin Evohaler, and Flovent HFA) were examined considering the joint effects of insertion angle (as above) and relative humidity at low (15%-25%) and high (>95%) conditions...When oriented toward the back of the oral cavity, the filter dose decreased from 46.5% to 36.9% for Ventolin Evohaler (p = 0.005) and from 56.7% to 44.2% for Flovent HFA (p < 0.001) at high humidity relative to low. High humidity may cause a reduction in total in vitro lung doses for some pMDI aerosols.
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Enrollment open:  Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia (clinicaltrials.gov) -  May 1, 2020   
    P4,  N=300, Recruiting, 
    High humidity may cause a reduction in total in vitro lung doses for some pMDI aerosols. Not yet recruiting --> Recruiting
  • ||||||||||  budesonide / Generic Mfg.
    Journal:  Nanoporous CD-MOF particles with uniform and inhalable size for pulmonary delivery of budesonide. (Pubmed Central) -  Oct 18, 2019   
    When Rhodamine B was carried by the DPI particles, the fluorescence signal at the lung tissue was markedly improved after cholesterol modification compared with CD-MOF, whilst the bioavailability of CHO-CD-MOF-BUD in rat was equivalent with that of the commercial product of Pulmicort Turbuhaler. Therefore, the CD-MOF powders modified by cholesterol can be used as a promising inhalable carrier for pulmonary delivery of drugs with small dose.
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Trial completion:  Inhaled Budesonide and Acute Mountain Sickness (clinicaltrials.gov) -  Oct 13, 2016   
    P1,  N=51, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Trial completion, Enrollment change, Trial primary completion date:  Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (clinicaltrials.gov) -  Jul 24, 2016   
    P4,  N=32, Completed, 
    Recruiting --> Completed Recruiting --> Completed | N=60 --> 32 | Trial primary completion date: Dec 2014 --> Feb 2016
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    New P1 trial:  Inhaled Budesonide and Acute Mountain Sickness (clinicaltrials.gov) -  Jun 23, 2016   
    P1,  N=51, Recruiting, 
  • ||||||||||  budesonide/formoterol / Generic mfg.
    Enrollment closed, Enrollment change:  SACOPD: Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) -  Oct 7, 2015   
    P4,  N=46, Active, not recruiting, 
    N=24 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2020 --> Jul 2016 Recruiting --> Active, not recruiting | N=60 --> 46
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Trial completion, Enrollment change:  PEACE-Peds: Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation (clinicaltrials.gov) -  Oct 2, 2015   
    P=N/A,  N=301, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Oct 2015 | Trial primary completion date: Apr 2020 --> Oct 2020 Active, not recruiting --> Completed | N=400 --> 301
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Enrollment change, Trial withdrawal:  The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton (clinicaltrials.gov) -  Jun 11, 2015   
    P4,  N=0, Withdrawn, 
    Active, not recruiting --> Completed | N=400 --> 301 N=60 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Trial completion:  Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia (clinicaltrials.gov) -  Feb 19, 2014   
    P2,  N=0, Completed, 
    Trial primary completion date: Dec 2013 --> Jul 2015 No longer recruiting --> Completed
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Trial completion:  Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide (clinicaltrials.gov) -  Feb 12, 2014   
    P=N/A,  N=20, Completed, 
    No longer recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Pulmicort Turbuhaler (budesonide dry-powder inhaler) / AstraZeneca
    Enrollment change:  ESTHER: Symbicort Rapihaler Therapeutic Equivalence Study (clinicaltrials.gov) -  Aug 13, 2012   
    P3,  N=742, Completed, 
    Recruiting --> Completed N=600 --> 742